Serum Biomarkers Analysis in Patients With AR Treated With Anti-TMF

Analysis of Circulant Rheumatoid Factor, Cyclic Citrullinated Anti-peptide Anti-bodies and Albumin as a Potential Predictor in the Response to the Treatment With Anti-TNF in Patients With Rheumatoid Arthritis

Multicenter, prospective, observational study for evaluating if circulant rheumatoid factor, cyclic citrullinated anti-peptide anti-bodies and albumin can be used as potential predictors in the response to the treatment with anti-TNF in patients with rheumatoid arthritis after 24 weeks of treatment.

Inclusion Criteria:

• Both genders
• Over 18 years old
• Diagnosis of rheumatoid arthritis according to ACR criteria
• Patients that initiate treatment with anti-TNF drugs according to clinical practice, both in naïve anti-TNF patients and patients after first anti-TNF failure
• Patients able to follow the protocol requirements
• Patients that signed the informed consent

Exclusion Criteria:

• Patients with known hypersensitivity to investigational products
• Patients with tuberculosis, or severe infections like sepsis or opportunistic infections
• Patients with moderate/severe cardiac insufficiency (NHYA classification Class III/IV)
• Patients that according to the investigator criteria can not participate in the study or complete the study questionnaires
• Pregnant or fertile woman that does not use a contraception method